ASX Stock to Launch on NASDAQ with Gut Busting Immunotherapy Products

Mar 24, 2017

Today’s $30 million capped ASX listed biotech player, which is in the process of listing on the NASDAQ, has thus far flown right under the radar of Australia’s biotech landscape. This scenario is likely to change, however, as this cutting edge company has chosen to take aim at the oral immunotherapy sector, with antibody products […]

Read Article

Could this ASX Cancer Therapy Junior Attract a Billion Dollar Big Pharma Deal?

Mar 16, 2017

One in every two Australians will be diagnosed with cancer by age 85. That’s a staggering statistic that has prompted a great deal of contemplation among doctors, patients and those affected in some way by the consequences of the disease. To try and combat the rise and spread of cancer, Big Pharma, along with smaller biotech companies are working on treatments and potential cures. One $30 million capped ASX junior may have a unique solution.

Read Article

First Cannabis Revenues in Sight for CPH

Nov 7, 2016

The medicinal cannabis industry, whilst attracting a lot of publicity, is still in its early stages as a new niche with very few current or even experienced market participants. Even the big pharma companies have so far been apprehensive towards taking significant stakes in medicinal cannabis, and have preferred to wait out the legislative rigmarole making headlines in the US, Europe and Australia.

Read Article

NOX Clinic Ready: Phase 1 Study Kicks off in Coming Weeks

Oct 26, 2016

Earlier this month, actor and director Ben Stiller publicised the fact he fought (and beat) an aggressive form of prostate cancer in 2014. He states his success over the oft-deadly disease is down to a PSA test that he took at an earlier age than what doctors commonly recommend.

Read Article
Be alerted as soon as an article is released - Join our mailing list (FREE)
  • close

Are you a sophisticated investor?